CASE REPORTSRituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura a case report and review of the literatureMontoya, Roberto C.; Poiesz, Bernard J. Author Information Department of Medicine, Upstate Medical University, Syracuse, New York, USA Correspondence to Bernard J. Poiesz, MD, Upstate Medical University, Syracuse, NY, USA. Tel: +1 315 464-8231; fax: +1 315 464-8255 Received 29 July, 2011 Revised 26 January, 2012 Accepted 14 February, 2012 Blood Coagulation & Fibrinolysis: June 2012 - Volume 23 - Issue 4 - p 338-341 doi: 10.1097/MBC.0b013e3283529184 Buy Metrics Abstract Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that most often arises from inhibition of the enzyme ADAMTS13 by autoantibodies. This provides the rationale for the use of rituximab, an anti-CD20 monoclonal antibody, as an effective treatment. Multiple reports have indicated success employing it in patients with TTP, but only a few have reported its use during remission as a prophylaxis to prevent a relapse. Herein, we report the case of a patient with chronic relapsing TTP who was successfully treated with prophylactic rituximab. We also provide a review of the literature on this topic. © 2012 Lippincott Williams & Wilkins, Inc.